Teva says making ‘great progress’ on Pivot to Growth strategy

Says Emalex acquisition not expected to impact 2027 targets or those beyond. Expects Emalex to be accretive to non-GAAP EPS and expected to contribute to margin expansion in 2028. Sees Orphan drug exclusivity (7 years post-approval) + additional IP. Sees mid-single digit revenue growth in 2030 and beyond with gross margins above 60%. Comments taken from Q1 earnings conference call.